Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.

A systematic review/meta-analysis was conducted to assess the effectiveness and safety of second-line treatments for advanced renal cell carcinoma (RCC), which includes the vascular endothelial growth factor inhibitor axitinib.